Marriott International Inc vs Novavax Inc — how do they compare? Marriott International Inc trades at $368.66 (market cap $96.76B), while Novavax Inc trades at $8.02 (market cap $1.30B). The key difference: Marriott International Inc is far larger — about 74.4× Novavax Inc's market cap, and Marriott International Inc pays a 0.8% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MAR | NVAX | |
|---|---|---|
Market Cap | $96.76B | $1.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $11.19 |
52-Week Low | $255.35 | $6.22 |
Enterprise Value | $113.71B | $800.50M |
Dividend Yield | 0.8% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.
The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.
Trailing returns across standard periods
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →